Yu Tao, Zhang Yonglian, Kerekes Angela D, Tagat Jayaram R, Doll Ronald J, Xiao Yushi, Esposite Sara, Hruza Alan, Belanger David B, Voss Matthew, Rainka Matthew P, Basso Andrea, Liu Ming, Liang Lianzhu, Sui Ning, Prelusky Daniel, Rindgen Diane, Zhang Likang
Department of Chemical Research, MRL 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA.
Department of Chemical Research, MRL 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA.
Bioorg Med Chem Lett. 2018 May 1;28(8):1397-1403. doi: 10.1016/j.bmcl.2018.02.037. Epub 2018 Feb 23.
Imidazo-[1, 2-a]pyrazine 1 is a potent inhibitor of Aurora A and B kinase in vitro and is effective in in vivo tumor models, but has poor oral bioavailbility and is unsuitable for oral dosing. We describe herein our effort to improve oral exposure in this class, resulting ultimately in the identification of a potent Aurora inhibitor 16, which exhibited good drug exposure levels across species upon oral dosing, and showed excellent in vivo efficacy in a mouse xenograft tumor model when dosed orally.
咪唑并-[1, 2-a]吡嗪1在体外是Aurora A和B激酶的有效抑制剂,在体内肿瘤模型中也有效,但口服生物利用度差,不适合口服给药。我们在此描述了我们为提高该类药物口服暴露量所做的努力,最终鉴定出一种有效的Aurora抑制剂16,该抑制剂口服给药后在各物种中均表现出良好的药物暴露水平,并且在小鼠异种移植肿瘤模型中口服给药时显示出优异的体内疗效。